{"id":"W4389280739","doi":"10.1016/j.annonc.2023.10.384","title":"258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prednisone; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00297907,0.0009004616,0.002337789,0.0003137513,0.0003202964,0.00146876,0.0005104647,0.0006114548,0.002885221],"category_scores_gemma":[0.001480985,0.0005422067,0.004324863,0.0005215271,0.0003672318,0.001052758,0.0005279296,0.00225504,0.0006542485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006041488,"about_ca_system_score_gemma":0.001244277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000940286,"about_ca_topic_score_gemma":0.003255025,"domain_scores_codex":[0.9988419,0.0005673257,0.00007151032,0.0002180523,0.0001103132,0.0001908747],"domain_scores_gemma":[0.9992297,0.0001494361,0.00021635,0.0001710153,0.00005852337,0.0001750679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8753389,0.002897843,0.05131769,0.0006523133,0.01555998,0.0001362325,0.0001342079,0.00230937,0.005335149,0.0003332884,0.004546244,0.04143892],"study_design_scores_gemma":[0.3596623,0.1647188,0.3933678,0.0004146135,0.04646332,0.0008262951,0.0005472076,0.007329913,0.005399602,0.002572274,0.01847084,0.0002270444],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865814,0.004290674,0.0007796284,0.0006077922,0.0003443577,0.0004477951,0.00357981,0.0001115415,0.003256948],"genre_scores_gemma":[0.9900706,0.001006789,0.0009752383,0.0006568939,0.0002340416,0.0005062104,0.004209106,0.00004124843,0.002299872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00297907,"threshold_uncertainty_score":0.015755,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08289055712942077,"score_gpt":0.3990372821216814,"score_spread":0.3161467249922606,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}